Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Atacama Labs Oy

Latest From Atacama Labs Oy

Start-Up Previews

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "The Drug Delivery Road Gets Tougher," features profiles of ActoGeniX, Atacama Labs, Glide Pharma and Mimetic Solutions. Plus these Start-Ups Across Health Care: Light Dimensions, Relyspa, Stentys and Thrombotargets.

The Drug Delivery Road Gets Tougher

While making money in drug delivery has always been tougher than its boosters have promised, this year's been ugly in new and disturbing ways. The key lessons of Pfizer's abandonment of inhaled insulin and Impax's patent assault on Endo's Opana are that partners are less reliable; the products need to be medically superior to existing ones, not simply more convenient; and generic companies are making inroads into the main bastion of drug-delivery success -- spec pharma.
BioPharmaceutical Business Strategies

Atacama Labs Oy

Atacama Labs aims to create better oral solid-dosage forms using a pneumatic dry granulation process that it claims can granulate virtually any active drug ingredient. To prove the worth of its technology to potential clients, Atacama has applied its method to two drugs that are notoriously difficult to dry-formulate: paracetamol for pain and metformin for diabetes. That mission has been accomplished, and now Atacama is inviting drug companies to send it proprietary compounds that they deem their most difficult to formulate.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Finland
  • Parent & Subsidiaries
  • Atacama Labs Oy
  • Senior Management
  • Steffen Mittwich, CEO
  • Contact Info
  • Atacama Labs Oy
    Phone: (358) 10 6179 901
    Life Science Center
    Keilaranta 14
    Espoo, 02150